Norinchukin Bank The cut its stake in shares of Humana Inc (NYSE:HUM) by 23.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 13,973 shares of the insurance provider’s stock after selling 4,287 shares during the quarter. Norinchukin Bank The’s holdings in Humana were worth $3,466,000 as of its most recent SEC filing.
Several other large investors also recently bought and sold shares of HUM. Sterling Capital Management LLC bought a new position in shares of Humana during the second quarter valued at approximately $253,000. Deschutes Portfolio Strategy LLC bought a new position in Humana in the 3rd quarter worth approximately $221,000. Robeco Institutional Asset Management B.V. grew its holdings in Humana by 5.1% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 137,119 shares of the insurance provider’s stock worth $33,403,000 after buying an additional 6,694 shares in the last quarter. Meeder Asset Management Inc. grew its holdings in Humana by 2.3% in the 3rd quarter. Meeder Asset Management Inc. now owns 23,101 shares of the insurance provider’s stock worth $5,628,000 after buying an additional 519 shares in the last quarter. Finally, Oakbrook Investments LLC bought a new position in Humana in the 3rd quarter worth approximately $1,523,000. 97.68% of the stock is owned by institutional investors.
Shares of Humana Inc (NYSE:HUM) opened at $269.00 on Tuesday. Humana Inc has a 52-week low of $203.36 and a 52-week high of $293.35. The company has a market capitalization of $37,037.08, a price-to-earnings ratio of 16.13, a PEG ratio of 1.45 and a beta of 0.93. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.61 and a current ratio of 1.85.
Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, February 7th. The insurance provider reported $2.06 EPS for the quarter, beating analysts’ consensus estimates of $2.00 by $0.06. Humana had a return on equity of 16.13% and a net margin of 4.55%. The company had revenue of $13.19 billion during the quarter, compared to the consensus estimate of $13.14 billion. During the same quarter in the prior year, the firm earned $2.34 EPS. The company’s quarterly revenue was up 2.4% compared to the same quarter last year. sell-side analysts forecast that Humana Inc will post 13.86 earnings per share for the current fiscal year.
Humana announced that its Board of Directors has initiated a stock repurchase plan on Thursday, December 14th that permits the company to buyback $3.00 billion in outstanding shares. This buyback authorization permits the insurance provider to repurchase shares of its stock through open market purchases. Shares buyback plans are generally an indication that the company’s leadership believes its shares are undervalued.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 27th. Stockholders of record on Friday, March 30th will be given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 0.74%. The ex-dividend date of this dividend is Wednesday, March 28th. This is an increase from Humana’s previous quarterly dividend of $0.40. Humana’s dividend payout ratio is 9.59%.
In other Humana news, VP Timothy S. Huval sold 1,382 shares of the business’s stock in a transaction on Tuesday, December 19th. The shares were sold at an average price of $246.04, for a total transaction of $340,027.28. Following the sale, the vice president now directly owns 11,557 shares of the company’s stock, valued at approximately $2,843,484.28. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Brian P. Leclaire sold 1,679 shares of the business’s stock in a transaction on Thursday, December 21st. The shares were sold at an average price of $245.97, for a total transaction of $412,983.63. Following the sale, the senior vice president now directly owns 9,888 shares in the company, valued at $2,432,151.36. The disclosure for this sale can be found here. Insiders have sold a total of 10,115 shares of company stock valued at $2,501,627 in the last quarter. Insiders own 0.80% of the company’s stock.
HUM has been the subject of a number of recent analyst reports. Credit Suisse Group initiated coverage on Humana in a report on Thursday, November 2nd. They issued a “neutral” rating and a $256.00 price objective for the company. Royal Bank of Canada reissued a “sector perform” rating and issued a $242.00 price objective (down from $245.00) on shares of Humana in a report on Thursday, November 9th. Morgan Stanley decreased their price objective on Humana from $276.00 to $270.00 and set an “overweight” rating for the company in a report on Thursday, November 9th. BMO Capital Markets increased their price objective on Humana from $290.00 to $300.00 and gave the stock an “outperform” rating in a report on Friday, November 10th. Finally, Cantor Fitzgerald reissued a “hold” rating and issued a $230.00 price objective on shares of Humana in a report on Tuesday, December 5th. Seven investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $270.47.
TRADEMARK VIOLATION NOTICE: This story was posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.thelincolnianonline.com/2018/02/20/norinchukin-bank-the-sells-4287-shares-of-humana-inc-hum.html.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.